TICKERNOMICS Sign up
Last Update: 2024-12-27 15:26:50
ATAI Life Sciences N.V. ( ATAI ) https://www.atai.life
1.25USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
Germany
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-16.11%
ATAI
SPY
32.66%
-82.95%
ATAI
SPY
108.59%
ATAI
0.00%
SPY
302.52%
ATAI
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
197.56
153.67
1.22
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-1.54
472.64
1.35
-41.88
0.00
-1.62
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-56505.00
100.00
-15125.72
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.32
-69.96
-34.00
0.00
Other Earnings and Cash Flow Stats:
ATAI Life Sciences N.V. ( ATAI ) Net Income TTM ($MM) is -128.60
ATAI Life Sciences N.V. ( ATAI ) Operating Income TTM ($MM) is -105.98
ATAI Life Sciences N.V. ( ATAI ) Owners' Earnings Annual ($MM) is 0.00
ATAI Life Sciences N.V. ( ATAI ) Current Price to Owners' Earnings ratio is 0.00
ATAI Life Sciences N.V. ( ATAI ) EBITDA TTM ($MM) is -105.63
ATAI Life Sciences N.V. ( ATAI ) EBITDA Margin is -15125.72%
Capital Allocation:
ATAI Life Sciences N.V. ( ATAI ) has paid 0.00 dividends per share and bought back -4.829327 million shares in the past 12 months
ATAI Life Sciences N.V. ( ATAI ) has reduced its debt by 15.896 million USD in the last 12 months
Capital Structure:
ATAI Life Sciences N.V. ( ATAI ) Interest-bearing Debt ($MM) as of last quarter is 1
ATAI Life Sciences N.V. ( ATAI ) Annual Working Capital Investments ($MM) are 50
ATAI Life Sciences N.V. ( ATAI ) Book Value ($MM) as of last quarter is 146
ATAI Life Sciences N.V. ( ATAI ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
ATAI Life Sciences N.V. ( ATAI ) has 29 million in cash on hand as of last quarter
ATAI Life Sciences N.V. ( ATAI ) has 19 million of liabilities due within 12 months, and long term debt 18 as of last quarter
ATAI Life Sciences N.V. ( ATAI ) has 160 common shares outstanding as of last quarter
ATAI Life Sciences N.V. ( ATAI ) has 0 million USD of preferred stock value
Academic Scores:
ATAI Life Sciences N.V. ( ATAI ) Altman Z-Score is -3.38 as of last quarter
ATAI Life Sciences N.V. ( ATAI ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
ATAI Life Sciences N.V. ( ATAI ) largest shareholder is owning shares at 0.00 ($MM) value
ATAI Life Sciences N.V.(an insider) Sold 2660000 shares of ATAI Life Sciences N.V. ( ATAI ) for the amount of $16093000.00 on 2024-09-26
9.99% of ATAI Life Sciences N.V. ( ATAI ) is held by insiders, and 26.77% is held by institutions
ATAI Life Sciences N.V. ( ATAI ) went public on 2021-06-18
Other ATAI Life Sciences N.V. ( ATAI ) financial metrics:
FCF:-79.26
Unlevered Free Cash Flow:-84.12
EPS:-0.65
Operating Margin:-56505.00
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-72.15
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About ATAI Life Sciences N.V. ( ATAI ) :
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA neurotransmitter systems to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the anxiety-related disorder treatment; and Neuronasal, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01 for TRD; and KUR-101, a formulation of deuterated mitragynine to treat OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.